BASF adds active drug substance to portfolio

Published: 16-Oct-2009
Ingredients Regulatory

BASF has added phenylephrine hydrochloride to its portfolio. The well-established substance is used in nasal sprays to helps nasal membranes to decongest.


BASF has added phenylephrine hydrochloride to its portfolio. The well-established substance is used in nasal sprays to helps nasal membranes to decongest.

This addition strengthens BASF's position on the global market for cold remedies. Phenylephrine hydrochloride is produced at the company's site in Minden, Germany, as it is ideally suited to the plants and technologies already in place. The pharmaceutical site also meets all cGMP (current Good Manufacturing Practice) guidelines and FDA requirements.

"The offering is BASF's response to increased demand for this tried and tested pharmaceutical ingredient. Phenylephrine is particularly popular in the US, the world's largest market for cold remedies," said Brigitte Sebastian, head of global marketing for active pharmaceutical ingredients at BASF.

  • Companies:
  • BASF Personal Care and Nutrition GmbH
See more

You may also like

Regulatory

US FDA accepts BASF Pharma Solutions’ excipient

Read more
Excipients (inactive ingredients) such as the Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Momentum in the US cannabidiol market gains retailers' attention Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

US FDA accepts BASF Pharma Solutions’ excipient

Excipients (inactive ingredients) such as the Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Ingredients

Five key takeaways from LogiChem EU 2019

Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community
Ingredients

BASF completes acquisition of Chemetall

BASF has completed its acquisition of Albemarle’s global surface treatment business, Chemetall
Ingredients

BASF inaugurates new PVP production facility in Shanghai, China

Will produce PVP K30 powder used as a base for pharma excipients and cosmetics
Ingredients

Colorcon to purchase BASF’s Kollicoat IR coating system product line

The two firms will also further their cooperation to offer superior functional coatings for pharmaceutical tablets
Ingredients

BASF introduces Kollicoat MAE 100-55 for formulation of enteric film coatings

Easier handling due to dust-free material
Manufacturing

BASF establishes speciality amine production plant in Ludwigshafen

BASF’s Intermediates division develops, produces and markets more than 700 intermediates, including amines, diols, polyalcohols and acids
Subscribe now